• 2006

    · Jusbio Sciences (Shanghai) Co., Ltd. was established. The company mainly engages in the R&D and manufacturing of Class IlI IVD reagents and instruments.

  • 2008

    · Shanghai Min-Sheng Med-Tech Co., Ltd. was established as a national first level agent for internationally renowned medical device products such as Roche Diagnostics.

  • 2013

    · Genovo Corporation was established in San Diego, California, United States. The company mainly engages in the R&D of IVD products and instruments of innovative biomarkers.

  • 2014

    · Shanghai Dunwill Medical Technology Co., Ltd. was established. It became the parent company of Jubio Sciences (Shanghai) Co., Ltd., Shanghai Min-Sheng Med-Tech Co., Ltd., Genovo Corporation, and Shanghai Epione Medlab Co., Ltd.

  • 2015

    · Zhongshan-Dunwill Center for Translational Theranostics was established after years of teamwork between Zhongshan Hospital Fudan University and Dunwill. Starting with the cooperation of clinical research and translation in the Liver Surgery and Liver Cancer Research Institute of Zhongshan Hospital, we further drill down to various research and translational projects with other departments in Zhongshan Hospital. Zhongshan-Dunwill Center for Translational Theranostics builds an innovation role model of an integration of medical institutions, R&D facilities and manufacturers.

  • 2016

    · SPF animal experiment facility was established.

  • 2017

    · Shanghai Epione Medlab Co., Ltd. was established. The company mainly provides molecular and pathological diagnostic testing services.

  • 2017

    · miRNA7 Test Kit was successfully launched. This product is the first liver cancer molecular testing kit approved in the world.

  • 2021

    · Shanghai Epione Medlab Co., Ltd. was accredited by CAP (College of American Pathologists) and passed multiple ability verifications with full score.

  • 2021

    · A deep cooperation project with Zhongshan Hospital Fudan University – “New diagnostic technologies and personalized treatment strategies for liver cancer based on liquid biopsy and omics platforms” won Second Prize of National Science and Technology Progress Award.

  • 2022

    · Shanghai Dunwill Medical Technology Co., Ltd. completed Round A equity financing of hundreds of millions of RMB.

  • 2023

    · Shanghai Dunwill Medical Technology Co., Ltd. held an inauguration ceremony of the new headquarters. The company relocated to the new location of Building 8, Songjiang Science and Technology City, Shanghai